Skip to main content

Table 6 Association between serum lipid biomarkers and the carrier status of the 14 bp indel in NCX1 intron 2

From: Hypervariable intronic region in NCX1 is enriched in short insertion-deletion polymorphisms and showed association with cardiovascular traits

      

Association testing using linear regression1

   

WT/WT

WT/indel

indel/

indel

Additive model

Dominant model

 

Sample2

n

Mean (± SD)

Mean (± SD)

Mean (± SD)

P-value

Effect (SE)

P-value

Effect (SE)

Total cholesterol

HYPEST

459

5.92 (1.15)

5.85 (1.24)

6.40 (2.47)

0.86

-0.02 (0.14)

0.73

-0.05 (0.15)

(mmol/L)

CADCZ

670

5.50 (1.04)

5.48 (0.99)

5.55 (0.83)

0.11

0.17 (0.11)

0.14

0.17 (0.11)

 

Meta-analysis

1129

5.67 (1.10)

5.63 (1.10)

5.98 (1.71)

0.25

0.10 (0.09)

0.33

0.09 (0.09)

 

Healthy subjects3

431

5.59 (1.07)

5.36 (0.98)

6.37 (0.00)

0.18

-0.19 (0.14)

0.14

-0.22 (0.15)

HDL (mmol/L)

HYPEST

458

1.52 (0.42)

1.46 (0.42)

1.38 (0.29)

0.23

-0.06 (0.05)

0.24

-0.06 (0.05)

 

CADCZ

670

1.41 (0.39)

1.41 (0.42)

1.42 (0.29)

0.81

-0.009 (0.04)

0.82

-0.01 (0.04)

 

Meta-analysis

1128

1.45 (0.41)

1.43 (0.42)

1.40 (0.26)

0.35

-0.03 (0.03)

0.37

-0.03 (0.03)

 

Healthy subjects3

431

1.52 (0.40)

1.61 (0.45)

1.70 (0.00)

0.10

0.09 (0.05)

0.10

0.09 (0.06)

LDL (mmol/L)

HYPEST

459

4.04 (1.03)

4.04 (1.00)

4.66 (2.58)

0.73

0.04 (0.12)

0.88

0.02 (0.13)

 

CADCZ

651

3.33 (0.89)

3.22 (0.85)

3.22 (0.63)

0.66

-0.09 (0.20)

0.57

-0.12 (0.21)

 

Meta-analysis

1110

3.63 (1.01)

3.54 (1.00)

3.94 (1.85)

0.94

0.01 (0.11)

0.87

-0.02 (0.11)

 

Healthy subjects3

427

3.41 (0.91)

3.13 (0.85)

3.94 (0.00)

0.06

-0.23 (0.12)

0.04

-0.26 (0.13)

Tri-glycerides

HYPEST

458

1.77 (1.66)

1.82 (1.02)

1.29 (0.53)

0.99

0.003 (0.19)

0.89

0.03 (0.20)

(mmol/L)

CADCZ

670

1.72 (1.19)

1.94 (1.27)

2.00 (1.16)

0.04

0.25 (0.12)

0.04

0.26 (0.12)

 

Meta-analysis

1128

1.74 (1.40)

1.89 (1.18)

1.65 (0.90)

0.08

0.18 (0.10)

0.07

0.19 (0.10)

 

Healthy subjects3

431

1.52 (1.12)

1.40 (0.81)

1.62 (0.00)

0.44

-0.11 (0.15)

0.42

-0.12 (0.15)

  1. 1For association analysis with serum lipids regression testing for a linear trend of marker alleles was performed with age, sex and BMI as covariates.
  2. 2Correction for the treatment with lipid-lowering medication was implemented as described[24].
  3. 3Pooled HYPEST and CADCZ control subjects with available records for serum lipids. The individuals had no personal history of cardiovascular disease, including essential hypertension, myocardial infarction, coronary artery disease, stroke, and had never been prescribed cardiovascular medications. Previously, no population differentiation was detected between HYPEST and CADCZ study subjects[18]
  4. n - number of individuals; Significant differences have been highlighted in bold, p < 0.05
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us